CK
MCID: CHK001
MIFTS: 53

Chikungunya (CK)

Categories: Blood diseases, Bone diseases, Infectious diseases, Rare diseases

Aliases & Classifications for Chikungunya

MalaCards integrated aliases for Chikungunya:

Name: Chikungunya 12 74 52 58 42 15
Chikungunya Fever 12 52 3 71
Arbovirus a Chikungunya Type 52
Chikungunya Virus Infection 52
Chikv Infection 52
Syndrome, Ck 39
Chik 52
Ck 52

Characteristics:

Orphanet epidemiological data:

58
chikungunya
Prevalence: <1/1000000 (France),<1/1000000 (Europe); Age of onset: All ages; Age of death: normal life expectancy;

Classifications:

Orphanet: 58  
Rare infectious diseases


External Ids:

Disease Ontology 12 DOID:0050012
ICD10 32 A92.0
ICD10 via Orphanet 33 A92.0
UMLS via Orphanet 72 C0008055
Orphanet 58 ORPHA324625
UMLS 71 C0008055

Summaries for Chikungunya

MedlinePlus : 42 Chikungunya is a virus that spread by the same kinds of mosquitoes that spread dengue and Zika virus. Rarely, it can spread from mother to newborn around the time of birth. It may also possibly spread through infected blood. There have been outbreaks of chikungunya virus in Africa, Asia, Europe, the Indian and Pacific Oceans, the Caribbean, and Central and South America. Most people who are infected will have symptoms, which can be severe. They usually start 3-7 days after being bitten by an infected mosquito. The most common symptoms are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, and rash. Most people feel better within a week. In some cases, however, the joint pain may last for months. People at risk for more severe disease include newborns, older adults, and people with diseases such as high blood pressure, diabetes, or heart disease. A blood test can show whether you have chikungunya virus. There are no vaccines or medicines to treat it. Drinking lots of fluids, resting, and taking non-aspirin pain relievers might help. The best way to prevent chikungunya infection is to avoid mosquito bites: Use insect repellent Wear clothes that cover your arms, legs, and feet Stay in places that have air conditioning or that use window and door screens Centers for Disease Control and Prevention

MalaCards based summary : Chikungunya, also known as chikungunya fever, is related to dengue virus and dengue disease, and has symptoms including fever, arthralgia and maculopapular rash. An important gene associated with Chikungunya is G3BP1 (G3BP Stress Granule Assembly Factor 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs chloroquine and Nonoxynol have been mentioned in the context of this disorder. Affiliated tissues include joint, testes and heart, and related phenotype is immune system.

Disease Ontology : 12 A viral infectious disease that results in infection located in joint, has material basis in Chikungunya virus, which is transmitted by Aedes mosquito bite. The infection has symptom fever, has symptom arthralgia, and has symptom maculopapular rash.

CDC : 3 Chikungunya virus is spread to people by the bite of an infected mosquito. The most common symptoms of infection are fever and joint pain. Other symptoms may include headache, muscle pain, joint swelling, or rash. Outbreaks have occurred in countries in Africa, Asia, Europe, and the Indian and Pacific Oceans. In late 2013, chikungunya virus was found for the first time in the Americas on islands in the Caribbean. There is a risk that the virus will be imported to new areas by infected travelers. There is no vaccine to prevent or medicine to treat chikungunya virus infection. Travelers can protect themselves by preventing mosquito bites. When traveling to countries with chikungunya virus, use insect repellent, wear long sleeves and pants, and stay in places with air conditioning or that use window and door screens.

Wikipedia : 74 Chikungunya is an infection caused by the chikungunya virus (CHIKV). Symptoms include fever and joint... more...

Related Diseases for Chikungunya

Diseases related to Chikungunya via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 581)
# Related Disease Score Top Affiliating Genes
1 dengue virus 33.2 RSAD2 OAS3 DDX58 CD209
2 dengue disease 31.4 TNF CD209 CCL5
3 west nile virus 31.3 RSAD2 DDX58 CD209
4 conjunctivitis 31.1 TNF IL6 CCL2
5 meningoencephalitis 31.1 TNF IL6 CCL5
6 yellow fever 31.1 STAT1 RSAD2 IL6 CCL5 CCL2
7 leptospirosis 30.9 TNF IL6 CCL2
8 neuritis 30.7 TNF IL6 CCL5 CCL2
9 encephalitis 30.7 TNF RSAD2 IL6 DDX58 CD209 CCL5
10 compartment syndrome 30.7 ZDHHC2 TNF IL6
11 stomatitis 30.6 TNF RSAD2 IL6 DDX58 BST2
12 bronchitis 30.6 TNF STAT1 IL6 CCL5
13 rubella 30.5 TNF IL6 DDX58
14 fuchs' heterochromic uveitis 30.5 IL6 CCL2
15 allergic encephalomyelitis 30.4 CCL5 CCL2
16 filariasis 30.4 TNF IL6 CCL5
17 japanese encephalitis 30.4 TNF TLR7 RSAD2 CD209 CCL5 CCL2
18 plague 30.4 TNF IL6 DDX58
19 perinatal necrotizing enterocolitis 30.3 TNF TLR7 IL6
20 gingivitis 30.3 TNF IL6 CCL5 CCL2
21 dengue hemorrhagic fever 30.3 TNF TLR7 STAT1 IL6 CD209
22 crimean-congo hemorrhagic fever 30.3 TNF IL6 FURIN DDX58
23 thrombocytopenia 30.2 TNF TLR7 STAT1 IL6 CD209 CCL2
24 proteasome-associated autoinflammatory syndrome 1 30.2 TNF IL6 CCL5 CCL2
25 tick-borne encephalitis 30.2 RSAD2 OAS3 DDX58 CD209
26 dengue shock syndrome 30.2 TNF IL6 CD209 CCL2
27 african tick-bite fever 30.2 TNF IL6 CCL5
28 pyelonephritis 30.2 TNF IL6 CCL5 CCL2
29 erythema multiforme 30.1 TNF IL6 CCL5
30 chorioamnionitis 30.1 TNF IL6 CCL2
31 adult-onset still's disease 30.1 TNF TLR7 IL6
32 toxoplasmosis 30.0 TNF STAT1 IL6
33 pertussis 30.0 TNF IL6 CCL5 CCL2
34 mumps 30.0 TNF STAT1 IL6
35 measles 29.9 TNF TLR7 STAT1 IL6 DDX58 CD209
36 fibromyalgia 29.9 TNF IL6 CCL2
37 meningitis 29.9 TNF IL6 CCL5 CCL2
38 chronic fatigue syndrome 29.9 TNF IL6 CCL5
39 viral infectious disease 29.7 TNF TLR7 STAT1 MAVS IL6 DDX58
40 kawasaki disease 29.6 TNF IL6 CCL2
41 herpes simplex 29.6 TNF STAT1 DDX58 CD209 CCL5
42 bone disease 29.6 TNF STAT1 IL6 CCL2
43 dermatitis, atopic 29.4 TNF TLR7 STAT1 IL6 CCL5 CCL2
44 human immunodeficiency virus type 1 29.2 TNF STAT1 IL6 CD209 CCL5 CCL2
45 immune deficiency disease 29.2 TNF STAT1 IL6 FURIN CD209 CCL5
46 severe acute respiratory syndrome 29.0 TNF STAT1 IL6 FURIN DDX58 CD209
47 ck syndrome 12.8
48 isolated elevated serum creatine phosphokinase levels 11.6
49 congenital hemidysplasia with ichthyosiform erythroderma and limb defects 11.5
50 neuroleptic malignant syndrome 11.5

Graphical network of the top 20 diseases related to Chikungunya:



Diseases related to Chikungunya

Symptoms & Phenotypes for Chikungunya

Symptoms:

12
  • fever
  • arthralgia
  • maculopapular rash

UMLS symptoms related to Chikungunya:


fever, pruritus

MGI Mouse Phenotypes related to Chikungunya:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.36 CCL2 CCL5 DDX58 FURIN IL6 MAVS

Drugs & Therapeutics for Chikungunya

Drugs for Chikungunya (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
2 Nonoxynol Phase 3
3 Contraceptive Agents Phase 3
4 Contraceptive Agents, Male Phase 3
5 Spermatocidal Agents Phase 3
6 Anti-Inflammatory Agents Phase 3
7 Anti-Inflammatory Agents, Non-Steroidal Phase 3
8 Antirheumatic Agents Phase 3
9 Analgesics Phase 3
10 Anti-Infective Agents Phase 3
11 Analgesics, Non-Narcotic Phase 3
12 Antiparasitic Agents Phase 3
13 Antiprotozoal Agents Phase 3
14 Antimalarials Phase 3
15 Chloroquine diphosphate Phase 3 50-63-5
16 Anthelmintics Phase 3
17
Aluminum hydroxide Approved, Investigational Phase 2 21645-51-2
18
Aluminum sulfate Approved Phase 2 10043-01-3
19 Immunoglobulins, Intravenous Phase 1, Phase 2
20 Rho(D) Immune Globulin Phase 1, Phase 2
21 gamma-Globulins Phase 1, Phase 2
22 Immunoglobulins Phase 2
23 Antibodies Phase 2
24 Pharmaceutical Solutions Phase 2
25 Vaccines Phase 2
26 Immunologic Factors Phase 2
27 Antibodies, Monoclonal Phase 1
28
Methotrexate Approved 1959-05-2, 59-05-2 126941
29
Methylprednisolone hemisuccinate Approved 2921-57-5
30
leucovorin Approved 58-05-9 6006 143
31
Methylprednisolone Approved, Vet_approved 83-43-2 6741
32
Prednisolone phosphate Approved, Vet_approved 302-25-0
33
Prednisolone Approved, Vet_approved 50-24-8 5755
34 Prednisolone acetate Approved, Vet_approved 52-21-1
35
Pantoprazole Approved 102625-70-7 4679
36
Mechlorethamine Approved, Investigational 51-75-2 4033
37
Ivermectin Approved, Investigational, Vet_approved 70288-86-7 6474909
38
Mebendazole Approved, Vet_approved 31431-39-7 4030
39
Albendazole Approved, Vet_approved 54965-21-8 2082
40
Folic acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
41
Prednisolone hemisuccinate Experimental 2920-86-7
42 Folic Acid Antagonists
43 Methylprednisolone Acetate
44 Dermatologic Agents
45 Folate
46 Vitamin B9
47 Vitamin B Complex
48 Immunosuppressive Agents
49 Antimetabolites
50 Sunflower

Interventional clinical trials:

(show top 50) (show all 58)
# Name Status NCT ID Phase Drugs
1 Randomized, Double-Blind, Controlled, Parallel Group Study With the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections and Treatment Use Open-Label Extension Study Recruiting NCT03037164 Phase 3
2 CuraChik : Double Blind Placebo-controlled Randomized Trial : Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease. Terminated NCT00391313 Phase 3 Chloroquine
3 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
4 Phase 2 Randomized, Placebo-Controlled Trial to Evaluate the Safety and Immunogenicity of a Chikungunya Virus-Like Particle Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Completed NCT02562482 Phase 2
5 Double Blinded, Randomized, Priorix®- and Placebo-controlled, Trial to Evaluate the Optimal Dose of MV-CHIK Vaccine (Against Chikungunya Virus) in Regard to Immunogenicity, Safety and Tolerability in Healthy Volunteers Completed NCT02861586 Phase 2
6 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in a Previously Epidemic Area Completed NCT03101111 Phase 2
7 Phase 2 Study of a Live Attenuated Measles Virus-Vectored Chikungunya Vaccine in Previously Exposed Adults Recruiting NCT03807843 Phase 2
8 Observer Blinded, Randomised Study to Investigate Safety, Tolerability and Long-term Immunogenicity of Different Dose Regimens and Formulations of MV-CHIK in Healthy Volunteers Active, not recruiting NCT03635086 Phase 2
9 A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted) Active, not recruiting NCT03483961 Phase 2
10 A Phase 2 Open-label Study to Assess the Safety and Immunogenicity of an Alum-adjuvanted Chikungunya Virus-like Particle Vaccine (PXVX0317) in Prior Recipients of Other Alphavirus Vaccines Versus Alphavirus naïve Controls. Not yet recruiting NCT03992872 Phase 2
11 A Phase 1, Double Blinded, Placebo Controlled, Dose Comparison Trial to Evaluate the Safety, Immunogenicity and Schedule of Measles-Vectored Chikungunya Virus Vaccine (MV-CHIK) in Healthy Adults Completed NCT03028441 Phase 1
12 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Chikungunya Virus (CHIKV) Vaccine ChAdOx1 Chik in Healthy Adult Volunteers Completed NCT03590392 Phase 1
13 A Randomized, Observer-Blinded, Dose-Escalation Phase 1 Study to Assess the Safety and Immunogenicity of Three Different Dose Levels of a Live-Attenuated Chikungunya Virus Vaccine Candidate (VLA1553) in Healthy Volunteers Aged 18 To 45 Years Completed NCT03382964 Phase 1
14 VRC 311: A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Virus-Like Particle (VLP) Chikungunya Vaccine, VRC-CHKVLP059-00-VP, in Healthy Adults Completed NCT01489358 Phase 1
15 Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine Completed NCT03055000 Phase 1
16 A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults Recruiting NCT03829384 Phase 1
17 A Phase I Study to Determine the Safety and Immunogenicity of the Candidate Zika Virus (ZIKV) Vaccine ChAdOx1 Zika in Healthy Adult Volunteers Given as a Standalone Vaccine or Co-administered With the Chikungunya Virus (CHIKV) Candidate Vaccine ChAdOx1 Chik Recruiting NCT04015648 Phase 1
18 A Phase 1, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of VAL-181388 in Healthy Adults in a Non Endemic Chikungunya Region Active, not recruiting NCT03325075 Phase 1
19 Study of the Prognostic Value of Musculoskeletal Ultrasound in Adults With Chikungunya Unknown status NCT02281123
20 A Pilot Study Examining for the Presence of Fecal Coliforms in Peruvian Water Sources and the Association of Tropical Diseases Within Peru Unknown status NCT03078894
21 Investigate the Prevalence of Serum Chikungunya Virus Infection, and Against Those Suspected Dengue Fever, Chikungunya Disease-related Tests Conducted Completed NCT02174341
22 Study of Zika Virus and Related Arbovirus Infections in Deferred Blood Donors Completed NCT02794181
23 Transcranial Direct Current Stimulation (tDCS) and Its Therapeutic Effects in Chikungunya Fever Completed NCT02993952
24 Efficacy of Starting Methotrexate Early in Chikungunya Arthritis:A 24 Week Randomized Controlled Open Label Crossover Trial Completed NCT03058471 Methotrexate;NSAID;Steroids
25 Effects of Auriculotherapy on Pain and Functional Capacity of Individuals With Chikungunya Fever Completed NCT03090685
26 Epidémie de Chikungunya à l'île de La Réunion : Effet à Dix Ans de l'Infection Sur la qualité de Vie Dans la Cohorte TELECHIK Completed NCT02901509
27 Seroprevalence of Chikungunya at the End of the First Chikungunya Outbreak in the French Antilles Within a Sample of Patients Treated for a HIV Infection Completed NCT02553369
28 A Pilot Study of the Pathogenesis of Chikungunya Arthritis in the Americas Completed NCT02463968
29 A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components Completed NCT02305732
30 The Evaluation of Potential Zika, Chikungunya, and Dengue Infections in Mexico (Zik01) Completed NCT02831699
31 Quantification of GADD34 Expression in Rheumatoid Arthritis Completed NCT02401165
32 Pilot Survey of Dengue Fever in Solomon Islands Completed NCT01868399
33 Prospective Surveillance and Case Definition Study of Zika Virus Disease and Infection in Adolescents and Adults in Latin America in Preparation for an Efficacy Trial of a Zika Virus Whole Virion, Purified Inactivated Vaccine Completed NCT03158233
34 Spatial Repellent Products for Control of Vector-borne Diseases - Dengue Completed NCT03553277
35 Rash Accompanied by Three or More Dengue-like Symptoms During Pregnancy and Microcephaly: Case-control Study Completed NCT02741882
36 Causes of Acute Undifferentiated Fever in Outpatients in the Democratic Republic of Congo Completed NCT02656862
37 Defining Skin Immunity of a Bite of Key Insect Vectors in Humans Completed NCT03641339
38 The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands Completed NCT01080989
39 Clinical Effectiveness of Standard Versus Pathogen-reduced Buffy Coat-derived Platelet Concentrates in Plasma in Hemato-oncological Patients. Completed NCT02783313
40 Genetic Factors and Immunological Determinism of Persistent Consequences of Chikungunya Fever: Genome-wide Association Study Recruiting NCT03690648
41 World Mosquito Program - Colombia (WMP-COLOMBIA): The Impact of City-wide Deployment of Wolbachia-infected Mosquitoes on Arboviral Disease Incidence in Medellin and Bello, Colombia Recruiting NCT03631719
42 Applying Wolbachia to Eliminate Dengue (AWED): A Non-blinded Cluster Randomised Controlled Trial to Assess the Efficacy of Wolbachia-infected Mosquito Deployments to Reduce Dengue Incidence in Yogyakarta, Indonesia Recruiting NCT03055585
43 Descriptive and Prognostic Study of Arbovirus Infections in France, Based on a Hospital Cohort of Children and Adults With Suspected Arbovirose.r Recruiting NCT01099852
44 Neurovirus Emerging in the Americas Study (NEAS): Neurologic Manifestations of the Arbovirus Dengue, Chikungunya and Zika Infections in Colombia Recruiting NCT03206541
45 World Mosquito Program Noumea - Human Sample Component Recruiting NCT03552094
46 Clinical Evaluation of the FilmArray® Global Fever (GF) Panel Recruiting NCT02968355
47 Estimated Cumulative Incidence of Zika Infection at the End of the First Epidemic in the French West Indies in a Sample of Patients Followed for HIV Infection. Recruiting NCT03161444
48 Study of Natural Killer Immunity During Infections With CMV or AdV After Allogeneic Hematopoietic Stem Cells Recruiting NCT03294824
49 An Open Label Study of IgG Fc Glycan Composition in Human Immunity Recruiting NCT01967238
50 A Prospective Study to Detect Novel Pathogens and Characterize Emerging Infections Recruiting NCT01979705

Search NIH Clinical Center for Chikungunya

Genetic Tests for Chikungunya

Anatomical Context for Chikungunya

The Foundational Model of Anatomy Ontology organs/tissues related to Chikungunya:

19
Joint

MalaCards organs/tissues related to Chikungunya:

40
Testes, Heart, T Cells, Bone, Kidney, Lung, Skin

Publications for Chikungunya

Articles related to Chikungunya:

(show top 50) (show all 4884)
# Title Authors PMID Year
1
In silico study of chikungunya polymerase, a potential target for inhibitors. 61 42
31803807 2019
2
Persistence of antibody response in chikungunya. 61 42
31803816 2019
3
Dengue fever and chikungunya virus infections: identification in travelers in Uganda - 2017. 61 42
31798935 2019
4
Return of the founder Chikungunya virus to its place of introduction into Brazil is revealed by genomic characterization of exanthematic disease cases. 61
31880218 2020
5
Genosensors for differential detection of Zika virus. 61
31987197 2020
6
Discovery of an Aedes (Stegomyia) albopictus population and first records of Aedes (Stegomyia) aegypti in Canada. 61
31566765 2020
7
Postmortem Chikungunya Diagnosis: A Case Report and Literature Review. 61
31977345 2020
8
Two distinct lineages of chikungunya virus cocirculated in Aruba during the 2014-2015 epidemic. 61
31786339 2020
9
Paper-based nucleic acid testing system for simple and early diagnosis of mosquito-borne RNA viruses from human serum. 61
31999593 2020
10
Impact on blood safety of the last arboviruses outbreaks in French Polynesia (2012-2018). 61
31889619 2020
11
Clinical relevance of Zika symptoms in the context of a Zika Dengue epidemic. 61
31399372 2020
12
Evaluation of the baited ovitrap with natural attractant for monitoring Aedes spp. in Dili, capital of East Timor. 61
32022206 2020
13
Nanostructured impedimetric lectin-based biosensor for arboviruses detection. 61
31816752 2020
14
"Submergence" of Western equine encephalitis virus: Evidence of positive selection argues against genetic drift and fitness reductions. 61
32027727 2020
15
Ovitraps Provide a Reliable Estimate of Wolbachia Frequency during wMelBr Strain Deployment in a Geographically Isolated Aedes aegypti Population. 61
32024068 2020
16
Habitat characteristics and insecticide susceptibility of Aedes aegypti in the Ifakara area, south-eastern Tanzania. 61
32033619 2020
17
Development and calibration of a model for the potential establishment and impact of Aedes albopictus in Europe. 61
31678121 2020
18
Successive blood meals enhance virus dissemination within mosquitoes and increase transmission potential. 61
31819213 2020
19
Chikungunya Case Classification after the Experience with Dengue Classification: How Much Time Will We Lose? 61
31769391 2020
20
Robustness of Serologic Investigations for Chikungunya and Mayaro Viruses following Coemergence. 61
32024703 2020
21
Genome sequences of chikungunya virus isolates from an outbreak in southwest Bangkok in 2018. 61
31834526 2020
22
Chikungunya virus replication in skeletal muscle cells is required for disease development. 61
31794434 2020
23
Chikungunya virus modulates the miRNA expression patterns in human synovial fibroblasts. 61
31483508 2020
24
Zika, chikungunya, and dengue infections as exacerbating factors of psoriasis in patients receiving biological therapy. 61
32039473 2020
25
Chikungunya infection: de-linking replication from symptomatology reveals the central role of muscle. 61
32039916 2020
26
Identification of 6'-β-fluoro-homoaristeromycin as a potent inhibitor of chikungunya virus replication. 61
31841728 2020
27
Evaluation of two commercially available chikungunya virus IgM enzyme-linked immunoassays (ELISA) in a setting of concomitant transmission of chikungunya, dengue and Zika viruses. 61
31704226 2020
28
Emergence of Chikungunya Virus, Pakistan, 2016-2017. 61
31967539 2020
29
Seroprevalence of yellow fever, dengue, West Nile and chikungunya viruses in children in Teso South Sub-County, Western Kenya. 61
31712089 2020
30
Zika virus: an emerging challenge to public health worldwide. 61
31682478 2020
31
Using Clinical Profiles and Complete Blood Counts to Differentiate Causes of Acute Febrile Illness during the 2009-11 Outbreak of Typhoid and Chikungunya in a Dengue Endemic Area. 61
32016406 2020
32
Pathogenetic Potential Relating to Metabolic Activity in a Mouse Model of Infection with the Chikungunya Virus East/Central/South African Genotype. 61
32028555 2020
33
Extensive Immunoinformatics study for the prediction of novel peptide-based epitope vaccine with docking confirmation against Envelope protein of Chikungunya virus: A Computational Biology Approach. 61
32037968 2020
34
Ophthalmic manifestations of arbovirus infections in adults. 61
31679764 2020
35
Using the Collaborative Requirements Development Methodology to Build Laboratory Capacity for Timely Diagnosis During the Zika Epidemic in Puerto Rico. 61
32011597 2020
36
Mutations in Hypervariable Domain of Venezuelan Equine Encephalitis Virus nsP3 Protein Differentially Affect Viral Replication. 61
31694937 2020
37
The Capsid Protein of Semliki Forest Virus Antagonizes RNA Interference in Mammalian Cells. 61
31694940 2020
38
Geographic shifts in the bioclimatic suitability for Aedes aegypti under climate change scenarios in Colombia. 61
31909268 2020
39
Lyophilized Matrix Containing Ready-to-Use Primers and Probe Solution for Standardization of Real-Time PCR and RT-qPCR Diagnostics in Virology. 61
32019076 2020
40
Sensitivity of alphaviruses to G3BP deletion correlates with efficiency of replicase polyprotein processing. 61
31941782 2020
41
Discovery of 1,2,4-oxadiazole derivatives as a novel class of noncompetitive inhibitors of 3-hydroxykynurenine transaminase (HKT) from Aedes aegypti. 61
31864777 2020
42
Reduced effectiveness of repellents in a pyrethroid-resistant strain of Aedes aegypti (Diptera: culicidae) and its correlation with olfactory sensitivity. 61
31338960 2020
43
Distribution and Frequency of the kdr Mutation V410L in Natural Populations of Aedes aegypti (L.) (Diptera: Culicidae) From Eastern and Southern Mexico. 61
31504686 2020
44
Aedes aegypti insecticide resistance underlies the success (and failure) of Wolbachia population replacement. 61
31919396 2020
45
In silico drug repurposing for the identification of potential candidate molecules against arboviruses infection. 61
31786251 2020
46
Developing vaccines against epidemic-prone emerging infectious diseases. 61
31776599 2020
47
Finding equipoise: CEPI revises its equitable access policy. 61
32005536 2020
48
Designing effective control of dengue with combined interventions. 61
31974303 2020
49
Geographical Genetic Variation and Sources of Korean Aedes albopictus (Diptera: Culicidae) Populations. 61
31972007 2020
50
Complementarity of empirical and process-based approaches to modelling mosquito population dynamics with Aedes albopictus as an example-Application to the development of an operational mapping tool of vector populations. 61
31951601 2020

Variations for Chikungunya

Expression for Chikungunya

Search GEO for disease gene expression data for Chikungunya.

Pathways for Chikungunya

Pathways related to Chikungunya according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 TNF TLR7 STAT1 RSAD2 PHB OAS3
2
Show member pathways
13.22 TNF STAT1 RSAD2 PHB OAS3 KPNA4
3
Show member pathways
12.96 TNF TLR7 STAT1 RSAD2 OAS3 MAVS
4
Show member pathways
12.86 TNF STAT1 IL6 CCL5 CCL2 BST2
5
Show member pathways
12.7 TNF MAVS IL6 DDX58 CCL5
6
Show member pathways
12.43 STAT1 RSAD2 OAS3 KPNA4 DDX58 BST2
7 12.37 TNF TLR7 STAT1 RSAD2 MAVS DDX58
8 12.3 TNF STAT1 OAS3 MAVS IL6 DDX58
9
Show member pathways
12.27 TNF IL6 CCL5 CCL2
10
Show member pathways
12.26 TNF IL6 CCL5 CCL2
11 12.18 TNF STAT1 IL6 CD209
12
Show member pathways
12.18 TNF STAT1 RSAD2 OAS3 IL6 BST2
13
Show member pathways
12.16 TNF STAT1 IL6 CD209
14 12.12 TNF TLR7 STAT1 IL6
15
Show member pathways
12.12 TNF TLR7 STAT1 IL6
16
Show member pathways
12.07 TNF TLR7 STAT1 RSAD2 OAS3 MAVS
17
Show member pathways
12 TNF TLR7 STAT1 IL6
18 11.96 TNF STAT1 OAS3 MAVS IL6 CCL5
19 11.93 TNF STAT1 IL6 CCL2
20 11.92 TNF IL6 CCL5 CCL2
21 11.86 TNF STAT1 IL6 CCL2
22 11.81 TNF IL6 CCL5 CCL2
23 11.69 TNF TLR7 IL6 CD209
24 11.66 TNF IL6 CCL5 CCL2
25 11.58 TNF IL6 CCL5 CCL2
26 11.49 TNF IL6 CCL2
27 11.42 TNF IL6 CCL5 CCL2
28
Show member pathways
11.09 STAT1 MAVS DDX58

GO Terms for Chikungunya

Cellular components related to Chikungunya according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.1 TNF PHB MXRA8 FURIN CD209 BST2

Biological processes related to Chikungunya according to GeneCards Suite gene sharing:

(show all 38)
# Name GO ID Score Top Affiliating Genes
1 immune response GO:0006955 10.05 TNF TLR7 OAS3 IL6 CCL5 CCL2
2 immune system process GO:0002376 10.05 TLR7 RSAD2 OAS3 MAVS G3BP1 DDX58
3 inflammatory response GO:0006954 10.03 TNF TLR7 IL6 CCL5 CCL2
4 cytokine-mediated signaling pathway GO:0019221 10 TNF STAT1 IL6 CCL5 CCL2
5 cellular protein metabolic process GO:0044267 9.96 ZDHHC2 MXRA8 IL6 FURIN
6 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.95 TNF PHB CCL5 CCL2
7 innate immune response GO:0045087 9.91 TLR7 RSAD2 OAS3 MAVS G3BP2 G3BP1
8 positive regulation of DNA-binding transcription factor activity GO:0051091 9.86 TNF MAVS IL6 DDX58
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.83 TNF IL6 CCL5
10 positive regulation of T cell proliferation GO:0042102 9.82 IL6 CD209 CCL5
11 humoral immune response GO:0006959 9.81 TNF IL6 CCL2
12 viral process GO:0016032 9.81 STAT1 RSAD2 MXRA8 MAVS KPNA4 G3BP2
13 cellular response to organic cyclic compound GO:0071407 9.8 TNF STAT1 CCL5 CCL2
14 response to virus GO:0009615 9.8 TNF RSAD2 OAS3 DDX58 CCL5 BST2
15 monocyte chemotaxis GO:0002548 9.79 IL6 CCL5 CCL2
16 protein kinase B signaling GO:0043491 9.78 TNF CCL5 CCL2
17 type I interferon signaling pathway GO:0060337 9.78 STAT1 RSAD2 OAS3 BST2
18 positive regulation of interleukin-6 secretion GO:2000778 9.77 TNF MAVS DDX58
19 lipopolysaccharide-mediated signaling pathway GO:0031663 9.76 TNF CCL5 CCL2
20 positive regulation of interleukin-6 production GO:0032755 9.76 TNF TLR7 IL6 DDX58
21 positive regulation of JAK-STAT cascade GO:0046427 9.74 TNF IL6 CCL5
22 positive regulation of smooth muscle cell proliferation GO:0048661 9.73 TNF STAT1 IL6 CCL5
23 positive regulation of defense response to virus by host GO:0002230 9.72 STAT1 MAVS DDX58
24 positive regulation of chemokine production GO:0032722 9.7 TNF TLR7 IL6
25 positive regulation of interleukin-8 biosynthetic process GO:0045416 9.68 TNF TLR7
26 positive regulation of neuroinflammatory response GO:0150078 9.67 TNF IL6
27 positive regulation of interferon-alpha secretion GO:1902741 9.67 MAVS DDX58
28 response to interferon-beta GO:0035456 9.67 STAT1 BST2
29 positive regulation of interleukin-8 production GO:0032757 9.67 TNF TLR7 MAVS DDX58
30 negative regulation of lipid storage GO:0010888 9.65 TNF IL6
31 positive regulation of T-helper 2 cell cytokine production GO:2000553 9.64 RSAD2 IL6
32 positive regulation of response to cytokine stimulus GO:0060760 9.64 MAVS DDX58
33 positive regulation of myeloid dendritic cell cytokine production GO:0002735 9.62 MAVS DDX58
34 positive regulation of interferon-beta secretion GO:0035549 9.62 MAVS DDX58
35 positive regulation of interferon-alpha production GO:0032727 9.58 STAT1 MAVS DDX58
36 positive regulation of stress granule assembly GO:0062029 9.54 G3BP2 G3BP1
37 negative regulation of viral genome replication GO:0045071 9.43 TNF RSAD2 OAS3 MAVS CCL5 BST2
38 defense response to virus GO:0051607 9.28 TLR7 STAT1 RSAD2 OAS3 MAVS IL6

Molecular functions related to Chikungunya according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 double-stranded RNA binding GO:0003725 9.33 TLR7 OAS3 DDX58
2 cytokine activity GO:0005125 9.26 TNF IL6 CCL5 CCL2
3 CCR5 chemokine receptor binding GO:0031730 8.62 STAT1 CCL5

Sources for Chikungunya

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....